“여탑 ┌ yeotop4 ¸ com송산동오피❟송산동풀싸롱❊송산동OPぐ송산동건마ぷ송산동오피❙송산동립카페ⅱ송산동안마”的搜索结果，显示 251-260 项，共有 6537 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Frailty is thought to be mediated by senescent cells and their dynamic secretome, referred to as the senescence-associated secretory phenotype (SASP). Senescent ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + ...

3. 妙佑医疗国际移植中心- 临床试验

   Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and ...

7. 神经科- 临床试验- 妙佑医疗国际

   The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable ...

10. 心血管医学- 临床试验- 妙佑医疗国际

    The Specific Aims of this study are: 1. To identify the genetic causes of bicuspid aortic valve disease and its associated thoracic aortic disease. 2. To ...